122 related articles for article (PubMed ID: 28746469)
1. Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.
Cao JY; Yin HS; Li HS; Yu XQ; Han X
Braz J Med Biol Res; 2017 Jul; 50(8):e6207. PubMed ID: 28746469
[TBL] [Abstract][Full Text] [Related]
2. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
Luo L; Cai L; Luo L; Tang Z; Meng X
Mol Med Rep; 2018 Jun; 17(6):8053-8060. PubMed ID: 29693700
[TBL] [Abstract][Full Text] [Related]
3. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
5. Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
Knievel J; Schulz WA; Greife A; Hader C; Lübke T; Schmitz I; Albers P; Niegisch G
Int J Mol Sci; 2014 Nov; 15(11):20500-17. PubMed ID: 25387078
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib regulating ERK signals pathway in gastric cancer cell.
Juan LW; En LM; Hao L; Kai HY; Ju H
Environ Toxicol Pharmacol; 2014 Sep; 38(2):438-43. PubMed ID: 25136776
[TBL] [Abstract][Full Text] [Related]
7. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
8. Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.
Rose A; Grandoch M; vom Dorp F; Rübben H; Rosenkranz A; Fischer JW; Weber AA
Br J Pharmacol; 2010 Aug; 160(7):1690-8. PubMed ID: 20649572
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.
Xu M; Zheng YL; Xie XY; Liang JY; Pan FS; Zheng SG; Lü MD
DNA Cell Biol; 2014 May; 33(5):275-81. PubMed ID: 24611881
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
11. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
12. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
14. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
15. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Pal HC; Diamond AC; Strickland LR; Kappes JC; Katiyar SK; Elmets CA; Athar M; Afaq F
Oncotarget; 2016 Jan; 7(2):1227-41. PubMed ID: 26517521
[TBL] [Abstract][Full Text] [Related]
16. 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib.
Chu JH; Zhao CR; Song ZY; Wang RQ; Qin YZ; Li WB; Qu XJ
Biomed Pharmacother; 2014 Apr; 68(3):335-41. PubMed ID: 24581722
[TBL] [Abstract][Full Text] [Related]
17. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
[TBL] [Abstract][Full Text] [Related]
18. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
19. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
Muche S; Kirschnick M; Schwarz M; Braeuning A
Anticancer Res; 2014 Sep; 34(9):4677-83. PubMed ID: 25202044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
